Follow The Filings

JNJ Johnson & Johnson

Johnson & Johnson earnings company data as of 7:45 PM ET 10/22

  • 1 of 1 EPS beats
  • 3 Owners
  • Rank #26
  • Max 2.6%
  • Master 0.05%

History

3 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q4 20 Jan EPS 2.93 — —
Rev $26.41B — —
FY2026 Q3 13 Oct EPS 2.95 — —
Rev $25.38B — —
FY2026 Q2 15 Jul EPS 2.84 2.90 Beat +2.1%
Rev $25.06B $25.31B Beat +1.0%

Who owns this now

Largest portfolio weights among holders, up to 2.6% (Kentucky Trust Co., Kentucky Trust). Not free-float ownership.

All holders
  1. Kentucky Trust Co. Reduce 2.6%
  2. Murphy Pohlad Reduce 1.2%
  3. David Katz 0.04%

Insider trades

Open-market buys and sales by JNJ's executives, directors and 10% owners in the last 12 months, from their Form 4s

All JNJ insider trades
  • $258K bought by 1 insider
  • $92.3M sold by 6 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Timothy Schmid Chair
    Sale
    $9.2M 33,597 shares at $274.74 57% of stake
    Traded Sep 2 Filed Sep 4
    ↗
  2. Jennifer L Taubert EVP, WWC. Innovative Medicine
    Sale
    $4M 15,000 shares at $263.36 7.2% of stake
    Traded Aug 17 Filed Aug 18
    ↗
  3. Joaquin Duato CEO
    Sale
    $32.2M 123,291 shares at $261.17 31% of stake
    Traded Aug 13 Filed Aug 14
    ↗
  4. Joaquin Duato CEO
    Sale
    $12.5M 48,480 shares at $258.15 15% of stake
    Traded Aug 5 Filed Aug 7
    ↗
  5. Elizabeth Forminard EVP, Chief Legal Officer
    Sale
    $4.1M 15,918 shares at $257.00 48% of stake
    Traded Aug 6 Filed Aug 7
    ↗
  6. Vanessa Broadhurst EVP, Global Corp Affairs
    Sale
    $5.8M 23,054 shares at $251.27 50% of stake
    Traded Jul 20 Filed Jul 21
    ↗
  7. Kathryn E Wengel EVP, Chief TO and Risk Officer
    Sale
    $2.4M 10,000 shares at $241.15 8% of stake
    Traded Jun 11 Filed Jun 12
    ↗
  8. Joaquin Duato CEO
    Sale
    $22.1M 100,000 shares at $221.23 76% of stake
    Traded Jan 26 Filed Jan 28
    ↗
  9. John G Morikis Director
    Buy
    $258K 1,250 shares at $206.15 +209% to stake
    Traded Nov 26, 2025 Filed Dec 1, 2025
    ↗
  10. John C Reed EVP, Innovative Medicine, R&D
    Sale
    $4.2M 21,721 shares at $192.71 67% of stake
    Traded Oct 17, 2025 Filed Oct 20, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 9 option exercises and 1 share withholding for taxes.

SEC filings

Recent issuer filings from EDGAR, 13 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.